Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $29.36 and traded as high as $30.25. Assembly Biosciences shares last traded at $29.68, with a volume of 62,216 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ASMB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Mizuho set a $40.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday, December 22nd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Assembly Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Assembly Biosciences Price Performance

The firm’s 50-day simple moving average is $29.19 and its 200 day simple moving average is $29.39. The firm has a market capitalization of $471.28 million, a price-to-earnings ratio of -6.22 and a beta of 1.11.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at $147,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at $228,000. Virtus Investment Advisers LLC acquired a new position in shares of Assembly Biosciences during the 4th quarter valued at $251,000. Finally, Engineers Gate Manager LP bought a new position in Assembly Biosciences during the fourth quarter worth $353,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.